Francisco Hernandez-Ilizaliturri, MD
Francisco Hernandez-Ilizaliturri, MD
Chief, Lymphoma Section
Professor of Oncology, Department of Medicine
Associate Professor, Department of Immunology
Roswell Park Comprehensive Cancer Center
Clinical Associate Professor of Medicine
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Is this your physician?
Or call 1-800-ROSWELL
Areas of Expertise:
Lymphoma
Multiple myeloma
Chronic lymphocytic leukemia
Special Interests:
Mechanisms associated with resistance to monoclonal antibodies in lymphoma patients
Developing new strategies to enhance the activity of therapies such as rituximab and other monoclonal antibodies
Background
Education and Training:
MD - InstitutoTecnologico y de Estudio Superiores de Monterrey, Monterrey, Mexico
Residency:
School of Medicine and Biomedical Sciences, State University of New York at Buffalo
Fellowship:
Roswell Park Cancer Institute, Buffalo, NY
Board Certification:
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
Professional Memberships:
American Association for Cancer Research Member
American Society of Hematology
American Society of Clinical Oncology
Honors and Awards:
June 2014 - Best Teacher award, Department of Medical Oncology, Roswell Park Comprehensive Cancer Center
- Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri FJ, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD. Outcomes of patient with double-hit lymphoma who achieve first complete remission. J Clin Oncol 2017 May 5:JCO22017722157 doi: 10.1200/JCO.2017.72.2157. [Epub ahead of print]. PMID: 28475457
- Czuczman MS, Trneny M, Davies A, Rule S, Linton KM, Wagner-Johnson N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri F, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Luh C-J, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res doi:10.1158/1078-0432.CCR-16-2818. [Epub ahead of print] 2017. PMID: 28381416
- Gu JJ, Kaufman GP, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. Mitotic catastrophe and cell cycle arrest are alternative cell deasth pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells. Oncotarget, 2016 Dec 31. Doi: 10.18632/oncotarget. 14405 [Epub ahead of print]. PMID: 28055975
- Czuczman N, Barth MJ, Gu J, Neppalli V, Mavis C, Frys S, Klener P, Vockova P, Czuczman MS, and Hernandez-Ilizaliturri FJ. Pevonedistat, a NEDD8 Activating Enzyme Inhibitor, is active in Mantle Cell Lymphoma and Enhances Rituximab Activity in vivo. Blood 127(9):1128-1137, 2015. Dec 16. pii: blood-2015-04-640920. [Epub ahead of print] PMID: 26675347.
- Barth M, Mavis C, Czuczman MS, and Hernandez-Ilizaliturri FJ. Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in pre-clinical models of mantle cell lymphoma. Clinical Cancer Research 21(19):4391-7497, 2015. Epub ahead of print 5/11/15. PMID: 25964296
Is this your physician?
Or call 1-800-ROSWELL